Camilla Skoglund

Camilla Skoglund

Auto-generated profile, based on publicly available information

Camilla Skoglund

Department of Health, Medicine, and Caring Sciences, Linköping University, Sweden (M.S., C.S., R.W.S.C., L.J.).

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LÅLinda Åkerman
Linda Åkerman
RCRosaura Casas
Rosaura Casas
JLJohnny Ludvigsson
Johnny Ludvigsson
BIBeatriz Tavira Iglesias
Beatriz Tavira Iglesias
CSCamilla Skoglund
Camilla Skoglund
Micro RNAs (miRNAs) are promising disease biomarkers due to their high stability. Their expression in serum is altered in type 1 diabetes, but whether deviations exist in individuals with high risk for type 1 diabetes remains unexplored. We therefore assessed serum miRNAs in high-risk individuals (n = 21) positive for multiple islet autoantibodies, age-matched healthy children (n = 17) and recent-onset type 1 diabetes patients (n = 8), using Serum/Plasma Focus microRNA PCR Panels from Exiqon. The miRNA levels in the high-risk group were similar to healthy controls, and no specific miRNA profile was identified for the high-risk group. However, serum miRNAs appeared to reflect glycemic status and ongoing islet autoimmunity in high-risk individuals, since several miRNAs were associated to glucose homeostasis and autoantibody titers. High-risk individuals progressing to clinical disease after the sampling could not be clearly distinguished from non-progressors, while miRNA expression in the type 1 diabetes group deviated significantly from high-risk individuals and healthy controls, perhaps explained by major metabolic disturbances around the time of diagnosis.

1 October 2010 in Clinical Immunology
Verified
Journal Article
Closed access
MCMikael Chéramy
Mikael Chéramy
CSCamilla Skoglund
Camilla Skoglund
IJIngela Johansson
Ingela Johansson
JLJohnny Ludvigsson
Johnny Ludvigsson
CHChristiane Susanne Hampe
Christiane Susanne Hampe
RCRosaura Casas
Rosaura Casas

Verified
Journal Article
Open access
PDF file
Mouna TabebiMouna Tabebi
Mouna Tabebi
RDRavi Kumar Dutta
Ravi Kumar Dutta
CSCamilla Skoglund
Camilla Skoglund
PSPeter Soderkvist
Peter Soderkvist
Oliver GimmOliver Gimm
Oliver Gimm
Background: Enzymes of tricarboxylic acid (TCA) have recently been recognized as tumor suppressors. Mutations in the SDHB subunit of succinate dehydrogenase (SDH) cause pheochromocytomas and paragangliomas (PCCs/PGLs) and predispose patients to malignant disease with poor prognosis. Methods: Using the human pheochromocytoma cell line (hPheo1), we knocked down SDHB gene expression using CRISPR-cas9 technology. Results: Microarray gene expression analysis showed that >500 differentially expressed gene targets, about 54%, were upregulated in response to SDHB knock down. Notably, genes involved in glycolysis, hypoxia, cell proliferation, and cell differentiation were up regulated, whereas genes involved in oxidative phosphorylation (OXPHOS) were downregulated. In vitro studies show that hPheo1 proliferation is not affected negatively and the cells that survive by shifting their metabolism to the use of glutamine as an alternative energy source and promote OXPHOS activity. Knock down of SDHB expression results in a significant increase in GLUD1 expression in hPheo1 cells cultured as monolayer or as 3D culture. Analysis of TCGA data confirms the enhancement of GLUD1 in SDHB mutated/low expressed PCCs/PGLs. Conclusions: Our data suggest that the downregulation of SDHB in PCCs/PGLs results in increased GLUD1 expression and may represent a potential biomarker and therapeutic target in SDHB mutated tumors and SDHB loss of activity-dependent diseases.

15 June 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
CSCamilla Skoglund
Camilla Skoglund
DADaniel Appelgren
Daniel Appelgren
IJIngela Johansson
Ingela Johansson
RCRosaura Casas
Rosaura Casas
JLJohnny Ludvigsson
Johnny Ludvigsson
Neutrophil extracellular traps (NETs) and mitochondrial DNA (mtDNA) are inflammatory mediators involved in the development of type 1 diabetes (T1D). Pancreas-infiltrating neutrophils can release NETs, contributing to the inflammatory process. Levels of NETs are increased in serum from patients with T1D and mtDNA is increased in adult T1D patients. Our aim was to investigate extracellular DNA (NETs, mtDNA and nuclear DNA) in children with newly diagnosed T1D and in children at high risk of the disease. We also elucidated if extracellular DNA short after diagnosis could predict loss of endogenous insulin production. Samples were analysed for mtDNA and nuclear DNA using droplet digital PCR and NETs were assessed by a NET-remnants ELISA. In addition, in vitro assays for induction and degradation of NETs, as well as analyses of neutrophil elastase, HLA genotypes, levels of c-peptide, IL-1beta, IFN and autoantibodies (GADA, IA-2A, IAA and ZnT8A) were performed. In serum from children 10 days after T1D onset there was an increase in NETs (p=0.007), mtDNA (p<0.001) and nuclear DNA (p<0.001) compared to healthy children. The elevated levels were found only in younger children. In addition, mtDNA increased in consecutive samples short after onset (p=0.017). However, levels of extracellular DNA short after onset did not reflect future loss of endogenous insulin production. T1D serum induced NETs in vitro and did not deviate in the ability to degrade NETs. HLA genotypes and autoantibodies, except for ZnT8A, were not associated with extracellular DNA in T1D children. Serum from children with high risk of T1D showed fluctuating levels of extracellular DNA, sometimes increased compared to healthy children. Therefore, extracellular DNA in serum from autoantibody positive high-risk children does not seem to be a suitable biomarker candidate for prediction of T1D. In conclusion, we found increased levels of extracellular DNA in children with newly diagnosed T1D, which might be explained by an ongoing systemic inflammation.

3 January 2014 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
TKT Kurz
T Kurz
MWM Weiner
M Weiner
CSC Skoglund
C Skoglund
SBS Basnet
S Basnet
PEP Eriksson
P Eriksson
MSM Segelmark
M Segelmark
Summary: A myelopoiesis gene signature in circulating leucocytes, exemplified by increased myeloperoxidase (MPO) and proteinase 3 (PR3) mRNA levels, has been reported in patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV), and to a lesser extent during remission. We hypothesized that this signature could predict disease relapse. mRNA levels of PR3, MPO, selected myelopoiesis transcription factors [CCAAT/enhancer binding protein α (CEBP-α), CCAAT/enhancer binding protein β (CEBP-β), SPI1/PU.1-related transcription factor (SPIB), spleen focus forming virus proviral integration oncogene, PU.1 homologue (SPI1)] and microRNAs (miRNAs) from patient and control peripheral blood mononuclear cells (PBMC) and polymorphonuclear cells (PMN) were analysed and associated with clinical data. Patients in stable remission had higher mRNA levels for PR3 (PBMC, PMN) and MPO (PBMC). PR3 and SPIB mRNA correlated positively in controls but negatively in patient PBMC. Statistically significant correlations existed between PR3 mRNA and several miRNAs in controls, but not in patients. PR3/MPO mRNA levels were not associated with previous or future relapses, but correlated with steroid treatment. Prednisolone doses were negatively linked to SPIB and miR-155-5p, miR-339-5p (PBMC) and to miR-221, miR-361 and miR-505 (PMN). PR3 mRNA in PBMC correlated with time since last flare, blood leucocyte count and estimated glomerular filtration rate. Our results show that elevated leucocyte PR3 mRNA levels in AAV patients in remission do not predict relapse. The origin seems multi-factorial, but to an important extent explainable by prednisolone action. Gene signatures in patients with AAV undergoing steroid treatment should therefore be interpreted accordingly.

16 August 2011 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
CSCamilla Skoglund
Camilla Skoglund
MCMikael Chéramy
Mikael Chéramy
RCRosaura Casas
Rosaura Casas
JLJohnny Ludvigsson
Johnny Ludvigsson
CHChristiane Susanne Hampe
Christiane Susanne Hampe
Skoglund C, Chéramy M, Casas R, Ludvigsson J, Hampe CS. GAD autoantibody epitope pattern after GAD‐alum treatment in children and adolescents with type 1 diabetes. Aims: We have previously shown that two injections of glutamic acid decarboxylase formulated in alum (GAD‐alum) preserved residual insulin secretion in children and adolescents with recent onset type 1 diabetes (T1D), and was accompanied by increased GAD autoantibody (GADA) titers. The aim of this study was to investigate whether GAD‐alum treatment affected the GADA epitope pattern. Methods: Serum samples from patients treated with GAD‐alum (n = 33) or placebo (n = 27), at baseline, 1, 3, 9, and 15 months after the initial injection, were tested for their binding capacity to specific GADA epitopes in an epitope‐specific radioligand binding assay with six recombinant Fab (rFab) (b96.11, DPA, DPD, MICA3, b78, and N‐GAD65 mAb). Results: No significant differences in variability of binding to any of the tested rFab were observed from baseline to 15 months. There was a sustained low binding of GADA to the b78‐ and N‐GAD65 mAb‐defined epitopes, often recognized by GADA in patients with stiff person syndrome (SPS) and seldom in T1D patients. However, binding of GADA to the T1D‐associated b96.11‐defined epitope increased between baseline and 3 months in GAD‐alum (−8.1%, min −72.4%, max 39.6%) compared to placebo patients (1.5%, min −28.3%, max 28.6%) (p = 0.02). Subsequently, the b96.11‐defined epitope recognition returned to levels similar to that observed at baseline. Conclusions: GAD‐alum injections did not affect binding of GADA to SPS‐related epitopes, further supporting the safety of the treatment. There were no changes in GADA epitope specificity to the T1D‐related epitopes, except for a temporarily increased binding to one of the tested epitopes.